Security National Bank Sells 50,512 Shares of Zoetis Inc. $ZTS

Security National Bank lessened its stake in Zoetis Inc. (NYSE:ZTS) by 93.8% in the fourth quarter, HoldingsChannel reports. The fund owned 3,358 shares of the company’s stock after selling 50,512 shares during the period. Security National Bank’s holdings in Zoetis were worth $423,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of ZTS. Global Wealth Strategies & Associates bought a new stake in shares of Zoetis in the 4th quarter valued at about $25,000. Lodestone Wealth Management LLC bought a new position in Zoetis during the 4th quarter valued at approximately $30,000. KERR FINANCIAL PLANNING Corp bought a new position in Zoetis during the 3rd quarter valued at approximately $31,000. Holos Integrated Wealth LLC bought a new position in Zoetis during the 4th quarter valued at approximately $32,000. Finally, Board of the Pension Protection Fund bought a new position in Zoetis during the 4th quarter valued at approximately $38,000. Institutional investors own 92.80% of the company’s stock.

Insiders Place Their Bets

In other news, Director Frank A. Damelio bought 6,650 shares of Zoetis stock in a transaction on Wednesday, May 13th. The shares were purchased at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares of the company’s stock, valued at approximately $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Paul Bisaro bought 2,000 shares of Zoetis stock in a transaction on Wednesday, May 13th. The shares were purchased at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the acquisition, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have bought 11,650 shares of company stock worth $886,384. Company insiders own 0.22% of the company’s stock.

Zoetis Stock Down 1.8%

ZTS stock opened at $74.11 on Friday. Zoetis Inc. has a fifty-two week low of $72.38 and a fifty-two week high of $172.23. The business’s 50 day moving average price is $112.28 and its two-hundred day moving average price is $120.94. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The company has a market capitalization of $31.07 billion, a price-to-earnings ratio of 12.29, a price-to-earnings-growth ratio of 1.21 and a beta of 0.87.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter last year, the company posted $1.48 EPS. The firm’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, analysts forecast that Zoetis Inc. will post 6.91 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on ZTS shares. UBS Group lowered their price target on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research report on Friday, May 8th. Morgan Stanley reaffirmed an “overweight” rating and set a $115.00 price target on shares of Zoetis in a research report on Friday. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday, May 2nd. Piper Sandler reaffirmed a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Finally, Stifel Nicolaus set a $105.00 price target on Zoetis in a research report on Friday, May 8th. Seven research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $137.50.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.